+

US7977342B2 - HCV inhibiting bi-cyclic pyrimidines - Google Patents

HCV inhibiting bi-cyclic pyrimidines Download PDF

Info

Publication number
US7977342B2
US7977342B2 US11/684,288 US68428807A US7977342B2 US 7977342 B2 US7977342 B2 US 7977342B2 US 68428807 A US68428807 A US 68428807A US 7977342 B2 US7977342 B2 US 7977342B2
Authority
US
United States
Prior art keywords
compound
formula
mmol
chloro
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US11/684,288
Other languages
English (en)
Other versions
US20070155716A1 (en
Inventor
Kenneth Alan Simmen
Tse-I Lin
Oliver Lenz
Dominique Louis Nestor Ghislain Surleraux
Pierre Jean-Marie Bernard Raboisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Infectious Diseases Diagnostics BVBA
Janssen R&D Ireland ULC
Original Assignee
Tibotec Virco Virology BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35448001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7977342(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Virco Virology BVBA filed Critical Tibotec Virco Virology BVBA
Assigned to TIBOTEC BVBA reassignment TIBOTEC BVBA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LENZ, OLIVER, LIN, TSE-I, RABOISSON, PIERRE JEAN-MARIE BERNARD, SIMMEN, KENNETH ALAN, SURLERAUX, DOMINIQUE LOUIS NESTOR GHISLAIN
Publication of US20070155716A1 publication Critical patent/US20070155716A1/en
Assigned to TIBOTEC PHARMACEUTICALS LTD. reassignment TIBOTEC PHARMACEUTICALS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TIBOTEC BVBA
Application granted granted Critical
Publication of US7977342B2 publication Critical patent/US7977342B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.
  • the present invention relates to processes for preparation of such pharmaceutical compositions.
  • the present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
  • HCV hepatitis C virus
  • HCV is a positive-sense, single-stranded RNA virus, with a genome of around 9,600 bp.
  • the genome comprises both 5′ and 3′ untranslated regions which adopt RNA secondary structures, and a central open reading frame that encodes a single polyprotein of around 3,010-3,030 amino acids.
  • the polyprotein encodes ten gene products which are generated from the precursor polyprotein by an orchestrated series of co- and post-translational endoproteolytic cleavages mediated by both host and viral proteases.
  • the viral structural proteins include the core nucleocapsid protein, and two envelope glycoproteins E1 and E2.
  • the non-structural (NS) proteins encode some essential viral enzymatic functions (helicase, polymerase, protease), as well as proteins of unknown function. Replication of the viral genome is mediated by an RNA-dependent RNA polymerase, encoded by non-structural protein 5b (NS5B).
  • NS5B non-structural protein 5b
  • the viral helicase and protease functions both encoded in the bifunctional NS3 protein, have been shown to be essential for replication of HCV RNA in chimpanzee models of infection (Kolykhalov, A. A., Mihalik, K., Feinstone, S. M., and Rice, C. M. J Virol. 74, 2046-2051, 2000).
  • HCV also encodes a metalloproteinase in the NS2 region.
  • HCV replicates preferentially in hepatocytes but is not directly cytopathic, leading to persistent infection. In particular, the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection.
  • HCV type 1 is the predominant genotype in the US and Europe. For instance, HCV type 1 accounts for 70 to 75 percent of all HCV infections in the United States.
  • the extensive genetic heterogeneity of HCV has important diagnostic and clinical implications, perhaps explaining difficulties in vaccine development and the lack of response to therapy. An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV).
  • HCV hepatitis C virus
  • liver fibrosis leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma)
  • HCC hepatocellular carcinoma
  • Liver cirrhosis due to HCV infection is responsible for about 10,000 deaths per year in the U.S.A. alone, and is the leading cause for liver transplantations.
  • Transmission of HCV can occur through contact with contaminated blood or blood products, for example following blood transfusion or intravenous drug use.
  • the introduction of diagnostic tests used in blood screening has led to a downward trend in post-transfusion HCV incidence.
  • the existing infections will continue to present a serious medical and economic burden for decades (Kim, W. R. Hepatology, 36, 5 Suppl. S30-S34, 2002).
  • HCV therapies are based on (pegylated) interferon-alpha (IFN- ⁇ ) in combination with ribavirin.
  • IFN- ⁇ interferon-alpha
  • This combination therapy yields a sustained virologic response in more than 40% of patients infected by genotype 1 viruses and about 80% of those infected by genotypes 2 and 3.
  • combination therapy has significant side effects and is poorly tolerated in many patients. For instance, in registration trials of pegylated interferon and ribavirin, significant side effects resulted in discontinuation of treatment in approximately 10 to 14 percent of patients.
  • Major side effects of combination therapy include influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms.
  • the development of more effective, convenient and tolerated treatments is a major public health objective.
  • By inhibiting the HCV replication a rapid reduction in the viral loads of patients infected with the hepatitis C virus is achieved.
  • a reduction of the viral load is a proof of principle of the clinical antiviral activity of HCV inhibitors.
  • HCC hepatocellular carcinoma
  • the compounds used in the present invention are derivatives of pyrimidine or triazine.
  • PCT publication WO01/47921 describes pyrimidine and triazine compounds that are inhibitors of kinase activities associated with various inflammatory conditions.
  • PCT publications WO00/12497 and WO02/076976 describe quinazoline derivatives that are inhibitors of TGFOR receptor kinase and TGF- ⁇ mediated signaling.
  • WO04/087056 relates to bi-cyclic pyrimidine inhibitors of TGF- ⁇ , in which a pyrimidine nucleus is bridged at the (5) and (6) position and are further substituted at positions (2) and (4) with substituents comprising aromatic moieties. These compounds are useful in treating subjects with conditions ameliorated by inhibition of TGF ⁇ activity.
  • WO03/097615 concerns methods of treating fibroproliferative disorders associated with TGF- ⁇ signaling, by administering non-peptide small molecule inhibitors of TGF- ⁇ specifically binding to the type I TGF- ⁇ receptor (TGF ⁇ -R1).
  • the inhibitors are quinazoline derivatives.
  • WO04/065392 relates to condensed pyridines and pyrimidines and their use as ALK-5 receptor ligands. These compounds are therapeutically active, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor ⁇ (TGF- ⁇ ). Pharmaceutical compositions for use in such therapy are disclosed.
  • TGF- ⁇ transforming growth factor ⁇
  • WO03/078426 discloses azolylaminoazines as inhibitors of protein kinases, pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various disease, conditions, or disorders.
  • WO03/078427 discloses azolylaminoazines as inhibitors of protein kinases, pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various disease, conditions, or disorders.
  • WO2003077921 discloses azinylaminoazoles as inhibitors of protein kinases, pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various disease, conditions, or disorders.
  • WO03/078423 discloses compounds useful as inhibitors of protein kinases, pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various disease, conditions, or disorders.
  • WO02/22601 describes pyrazole compositions comprising a pharmaceutically acceptable carrier and compounds which are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
  • the compounds of the present invention are pyrimidine derivatives which contain a fused ring bridging positions 5 and 6.
  • the compounds are of the formula
  • fused ring bridging positions 5 and 6 of the pyrimidine ring is saturated, unsaturated or aromatic.
  • the fused ring is an optionally substituted ring and contains 4-7 members, where each member is independently C, N, O or S. However, if said fused ring contains 6 members, it is not aromatic.
  • Each of Ar 1 and Ar 2 is independently an optionally substituted aromatic moiety or optionally substituted heteroaromatic moiety wherein said heteroaromatic moiety contains one or more O, S, and/or N; typically these moieties contain 5-12 members.
  • R 1 is H, or optionally substituted alkyl (1-10C), alkenyl (2-10C), or alkynyl (2-10C).
  • the compounds useful in the invention are derivatives of pyrimidine containing a bridge at positions 5-6 and mandatory substituents at positions corresponding to the 2- and 4-positions of pyrimidine. Further non-interfering substituents may also be included.
  • the present invention relates to the use of a compound of the formula
  • fused ring bridging positions 5 and 6 of the pyrimidine ring is an optionally substituted saturated, unsaturated or aromatic ring containing 4-7 members, wherein X is an atom selected from N, O, or S; n is 0, 1, 2, or 3; each of Ar 1 and Ar 2 is independently an optionally substituted aromatic moiety or optionally substituted heteroaromatic moiety wherein said heteroaromatic moiety contains one or more O, S, and/or N, and these aromatic or heteroaromatic moieties contain 5-12 members; R 1 is H, or optionally substituted alkyl (1-10C), alkenyl (2-10C), or alkynyl (2-10C); with the proviso that if said fused ring bridging positions 5 and 6 of the pyrimidine ring contains 6 members, it is not an aromatic ring; for the manufacture of a medicament useful for inhibiting HCV activity, preventing or treating conditions associated with HCV, in a mammal infected with H
  • a compound of the formula (1) for the manufacture of a medicament useful for preventing disease progression towards chronic hepatitis, liver fibrosis, cirrhosis, end-stage liver disease, HCC (hepatocellular carcinoma) and the like, in a mammal infected with HCV.
  • a compound of the formula (1) for the manufacture of a medicament useful for treating chronic hepatitis, liver fibrosis, cirrhosis, end-stage liver disease, HCC (hepatocellular carcinoma) and the like, in a mammal infected with HCV.
  • the compounds useful in the invention are derivatives of pyrimidine containing a bridge at positions 5-6 and mandatory substituents at positions corresponding to the 2- and 4-positions of pyrimidine. Further non-interfering substituents may also be included.
  • the Ar 1 and Ar 2 are each independently an optionally substituted aromatic moiety or optionally substituted heteroaromatic moiety wherein said heteroaromatic moiety contains one or two O, S, and/or N, and these aromatic or heteroaromatic moieties contain 5-12 members.
  • the present invention relates to the use of a compound of the formula
  • fused ring bridging positions 5 and 6 of the pyrimidine ring is an optionally substituted saturated, unsaturated or aromatic ring containing 5 or 6 members, wherein X is an atom selected from N or O; n is 0, 1, or 2; each of Ar 1 and Ar 2 is independently an optionally substituted aromatic moiety or optionally substituted heteroaromatic moiety wherein said heteroaromatic moiety contains one or two N, and these aromatic or heteroaromatic moieties contain 5-7 members; R 1 is H, or optionally substituted alkyl (1-10C); with the proviso that if said fused ring bridging positions 5 and 6 of the pyrimidine ring contains 6 members, it is not an aromatic ring; for the manufacture of a medicament useful for inhibiting HCV activity, preventing or treating conditions associated with HCV, in a mammal infected with HCV.
  • the present invention relates to the use of a compound of the formula
  • fused ring bridging positions 5 and 6 of the pyrimidine ring is an optionally substituted saturated, unsaturated or aromatic ring containing 5 or 6 members, wherein X is an atom selected from N or O; n is 0, 1, or 2; each of Ar 1 and Ar 2 is independently an optionally substituted phenyl or an optionally substituted pyridiyl; R 1 is H, or optionally substituted alkyl (1-6C); with the proviso that if said fused ring bridging positions 5 and 6 of the pyrimidine ring contains 6 members, it is not an aromatic ring; for the manufacture of a medicament useful for inhibiting HCV activity, preventing or treating conditions associated with HCV, in a mammal infected with HCV.
  • the present invention relates to the use of a compound of the formula
  • fused ring bridging positions 5 and 6 of the pyrimidine ring is an optionally substituted saturated, unsaturated or aromatic ring containing 5 or 6 members, wherein X is an atom selected from N or O; n is 0, 1, or 2; R 1 is H, or optionally substituted alkyl (1-6C); each R 3 is, independently, hydrogen, halo, cyano, nitro, alkyl(1-6C), polyhaloalkyl(1-6C), —COR, —CONR 2 , —COOR, —OR, —OCOR, —NR 2 , or —NRCOR; each R 4 is, independently, hydrogen, halo, cyano, nitro, polyhaloalkyl(1-6C), or alkyl(1-6C); wherein each R is independently hydrogen, hydroxy, amino, mono- or dialkyl(1-6C)amino, cycloalkyl(3-7C), Het, or alkyl(1-6C)
  • the present invention relates to the use of a compound of the formula
  • R 3 is hydrogen, halo, alkyl(1-6C), —CF 3 , —COR, —CONR 2 , or —COOR;
  • each R 4a R 4b are, independently, hydrogen or halo; wherein each R is independently hydrogen, hydroxy, amino, mono- or dialkyl(1-6C)amino, cycloalkyl(3-7C), Het, or alkyl(1-6C) optionally substituted with one or two substituents selected from hydroxy, cycloalkyl(3-7C), amino, mono- or dialkyl(1-6C)amino, and Het;
  • Het is a group selected from
  • group Het may be optionally substituted with one or two substituents each independently selected from the group consisting of alkyl(1-6C), and oxo; for the manufacture of a medicament useful for inhibiting HCV activity, preventing or treating conditions associated with HCV, in a mammal infected with HCV.
  • the present invention relates to the use of a compound of the formula
  • R 3 is hydrogen, alkyl(1-6C), or —CONR 2 ; each R 4a R 4b are, independently, hydrogen or halo; wherein each R is independently hydrogen, amino, mono- or dialkyl(1-6C)amino, or alkyl(1-6C) optionally substituted with one hydroxy; for the manufacture of a medicament useful for inhibiting HCV activity, preventing or treating conditions associated with HCV, in a mammal infected with HCV.
  • a “noninterfering substituent” is a substituent which leaves the ability of the compound of formula (1) to inhibit HCV activity qualitatively intact. Thus, the substituent may alter the degree of inhibition, but as long as the compound of formula (1) retains the ability to inhibit activity, the substituent will be classified as “noninterfering.”
  • alkyl As used herein, the term “alkyl,” “alkenyl” and “alkynyl” include straight-chain, branched-chain and cyclic monovalent substituents, containing only C+H when they are unsubstituted. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like. Typically, the alkyl, alkenyl and alkynyl substituents contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-6C (lower alkyl) or 2-6C (lower alkenyl or lower alkynyl).
  • Heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain 1 or more O, S or N heteroatoms or combinations thereof within the backbone residue.
  • acyl encompasses the definitions of alkyl, alkenyl, alkynyl, and heteroacyl includes the related heteroforms, each of which are coupled to an additional residue through a carbonyl group.
  • arylalkyl and heteroarylalkyl refer to aromatic and heteroaromatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-8C, or the hetero forms thereof. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl or heteroacyl moiety.
  • polyhaloalkyl(1-6C) as a group or part of a group is defined as mono- or polyhalo substituted alkyl(1-6C), in particular alkyl(1-6C) substituted with up to one, two, three, four, five, six, or more halo atoms, such as methyl or ethyl with one or more fluoro atoms, for example, difluoromethyl, trifluoromethyl, trifluoroethyl. Preferred is trifluoromethyl.
  • perfluoroalkyl(1-6C) groups which are alkyl(1-6C) groups wherein all hydrogen atoms are replaced by fluoro atoms, e.g. pentafluoroethyl. In case more than one halogen atom is attached to an alkyl group within the definition of polyhaloalkyl(1-6C), the halogen atoms may be the same or different.
  • any alkyl, alkenyl, alkynyl, acyl, or aryl group contained in a substituent may itself optionally be substituted by additional substituents.
  • the nature of these substituents is similar to those recited with regard to the primary substituents themselves.
  • this alkyl may optionally be substituted by the remaining substituents listed as substituents where this makes chemical sense, and where this does not undermine the size limit of alkyl per se; e.g., alkyl substituted by alkyl or by alkenyl would simply extend the upper limit of carbon atoms for these embodiments.
  • alkyl substituted by aryl, amino, alkoxy, and the like would be included.
  • the features of the invention compounds are defined by formulae (1), (2), and (3) and the nature of the substituents is less important as long as the substituents do not interfere with the stated biological activity of this basic structure.
  • halo is generic to fluoro, chloro, bromo and iodo.
  • oxo or ( ⁇ O) forms a carbonyl moiety when attached to a carbon atom.
  • the carbon atom to which the oxo is linked is a saturated carbon.
  • Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated.
  • pyridyl includes 1-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl
  • pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
  • each definition is independent.
  • Non-interfering substituents on Ar 1 or Ar 2 include, but are not limited to, alkyl, alkenyl, alkynyl, halo, —OR, —NR 2 , —SR, —SOR, —SO 2 R, —OCOR, —NRCOR, —NRCONR 2 , —NRCOOR, —OCONR 2 , —RCO, —COOR, —NRSOR, —NRSO 2 R, —SO 3 R, —CONR 2 , SO 2 NR 2 , wherein each R is independently H or alkyl (1-8C), —CN, —CF 3 , and NO 2 , and like substituents.
  • Non-interfering substituents on Ar 1 or Ar 2 include, but are not limited to, alkyl, alkenyl, alkynyl, halo, —OR, —NR 2 , —SR, —SOR, —SO 2 R, —OCOR, —NRCOR, —NRCONR 2 , —NRCOOR, —OCONR 2 , —RCO, —COR, —COOR, —NRSOR, —NRSO 2 R, —SO 3 R, —CONR 2 , SO 2 NR 2 , wherein each R is independently H or alkyl (1-8C), —CN, —CF 3 , and NO 2 , and like substituents.
  • R are H, alkyl (1-10C) or a heteroatom-containing form thereof, each optionally substituted, especially (1-4C) alkyl; alkoxy (1-8C), acylamido, aryloxy, arylalkyloxy, especially wherein the aryl group is a phthalimido group, and alkyl or arylalkyl amine.
  • Ar 1 and Ar 2 are optionally substituted phenyl, 2-, 3- or 4-pyridyl, indolyl, 2- or 4-pyrimidyl, pyridazinyl, benzotriazolyl or benzimidazolyl. More preferably Ar 1 and Ar 2 are phenyl, pyridyl, or pyrimidyl. Preferably Ar 1 is pyridyl or pyrimidyl and Ar 2 is phenyl.
  • Each of these embodiments may optionally be substituted with a group such as alkyl, alkenyl, alkynyl, aryl, —O-aryl, —O-alkylaryl, —O-aroyl, —NR-aryl, —N-alkylaryl, —NR-aroyl, halo, —OR, —NR 2 , —SR, —OOCR, —NROCR, —RCO, —COOR, —CONR 2 , and/or SO 2 NR 2 , wherein each R is independently H or alkyl (1-8C), and/or by —CN, —CF 3 , and/or NO 2 .
  • a group such as alkyl, alkenyl, alkynyl, aryl, —O-aryl, —O-alkylaryl, —O-aroyl, —NR-aryl, —N-alkylaryl, —NR-aroyl, halo,
  • Each of these embodiments may optionally be substituted with one or two groups such as alkyl, alkenyl, alkynyl, aryl, —O-aryl, —O-alkylaryl, —O-aroyl, —NR-aryl, —N-alkylaryl, —NR-aroyl, halo, —OR, —NR 2 , —SR, —OOCR, —OCOR, —NROCR, —NRCOR, —RCO, —COR, —COOR, —CONR 2 , and/or SO 2 NR 2 , wherein each R is independently H or alkyl (1-8C), and/or by —CN, —CF 3 , and/or NO 2 . Alkyl, alkenyl, alkynyl and aryl portions of these may be further substituted by similar substituents.
  • Preferred substituents on Ar 1 or Ar 2 include alkyl, alkenyl, alkynyl, halo, —OR, —SR, —NR 2 wherein R is H or alkyl (1-4C); and/or arylamino, arylalkylamino, including alkylamino which is substituted by more than one aryl.
  • any aryl or alkyl group included within a substituent may itself be substituted similarly.
  • These substituents may occupy all available positions of the ring, preferably 1-2 positions, or more preferably only one position.
  • any of the aryl moieties may also comprise two substituents which, when taken together, form a 5-7 membered carbocyclic or heterocyclic aliphatic ring.
  • the bridge between positions 5 and 6 of the pyrimidine ring forms a fused ring system wherein, if the fused ring contains 6 members, it is not aromatic. However, the bridge may contain pi bonds and may contain one or more heteroatoms which are selected from N, O, and S.
  • Preferred embodiments include those wherein the bridge results in a 5-membered ring optionally containing one or two nitrogens, a nitrogen and an oxygen, an oxygen, an additional double bond, a saturated bridge, or a 6-membered ring formed by a bridge which is saturated.
  • the 6-membered saturated bridge-generated ring contains one or two nitrogen.
  • the ring formed by the bridge may itself be substituted.
  • the substituents described above for Ar 1 and Ar 2 may also be present as fused ring systems.
  • the term “compounds of formula (1)”, “compounds of formula (2)”, “compounds of formula (3)”, or “the present compounds” or similar terms it is meant to include the compounds of formulae (1), (2), and (3), their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes, and stereochemically isomeric forms.
  • One embodiment comprises the compounds of formula (1) or any subgroup of compounds of formula (1) specified herein, including compounds of formula (2) and (3), as well as the N-oxides, salts, as the possible stereoisomeric forms thereof.
  • Another embodiment comprises the compounds of formula (1) or any subgroup of compounds of formula (1) specified herein, as well as the salts as the possible stereoisomeric forms thereof.
  • salts of the compounds of formula (1) are those wherein the counter-ion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (1) are able to form.
  • the pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
  • butanedioic acid benzoic, maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • salt forms can be converted by treatment with an appropriate base into the free base form.
  • the compounds of formula (1) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • the compound may also be supplied as a salt with a pharmaceutically acceptable cation.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • addition salt as used hereinabove also comprises the solvates which the compounds of formula (1) as well as the salts thereof, are able to form.
  • solvates are for example hydrates, alcoholates and the like.
  • the compounds of formula (1) may also be supplied in the form of a “prodrug” which is designed to release the compound of formula (1) when administered to a subject.
  • prodrug as used herein means the pharmacologically acceptable derivatives such as esters, amides and phosphates, such that the resulting in vivo biotransformation product of the derivative is the active drug as defined in the compounds of formula (I).
  • the reference by Goodman and Gilman The Pharmacological Basis of Therapeutics, 8 th ed, McGraw-Hill, Int. Ed. 1992, “Biotransformation of Drugs”, p 13-15) describing prodrugs generally is hereby incorporated.
  • Prodrugs preferably have excellent aqueous solubility, increased bioavailability and are readily metabolized into the active inhibitors in vivo.
  • Prodrugs of a compound of the present invention may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either by routine manipulation or in vivo, to the parent compound.
  • Prodrug formed designs are well known in the art, and depend on the substituents contained in the compound of formula (1).
  • a substituent containing sulfhydryl could be coupled to a carrier which renders the compound biologically inactive until removed by endogenous enzymes or, for example, by enzymes targeted to a particular receptor or location in the subject.
  • ester prodrugs that are hydrolysable in vivo and are derived from those compounds of formula (1) having a hydroxy or a carboxyl group.
  • An in vivo hydrolysable ester is an ester, which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • esters for carboxy include alkoxymethyl esters for example methoxymethyl, alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, cycloalkoxycarbonyloxyalkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl which may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolysable ester of a compound of the formula (1) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
  • a selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4-position of the benzoyl ring.
  • quaternary amine as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (1) are able to form by reaction between a basic nitrogen of a compound of formula (1) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide.
  • an appropriate quaternizing agent such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide.
  • Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates.
  • a quaternary amine has a positively charged nitrogen.
  • N-oxide forms of the present compounds are meant to comprise the compounds of formula (1) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide.
  • the compounds of formula (1) may have metal binding, chelating, complex forming properties and therefore may exist as metal complexes or metal chelates. Such metalated derivatives of the compounds of formula (1) are intended to be included within the scope of the present invention.
  • the compounds of formula (1) have several centers of chirality and exist as stereochemically isomeric forms.
  • stereochemically isomeric forms as used herein defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (1) may possess.
  • the compounds of formula (1) include all stereoisomeric forms thereof, both as isolated stereoisomers and mixtures of these stereoisomeric forms. Said mixtures may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or mixed with each other are intended to be embraced within the scope of the present invention.
  • stereoisomerically pure concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e.
  • Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures.
  • enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid.
  • enantiomers may be separated by chromatographic techniques using chiral stationary phases.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereo specifically.
  • the diastereomeric racemates of the compounds of formula (1) can be obtained separately by conventional methods.
  • Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
  • a person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction.
  • the present invention is also intended to include all isotopes of atoms occurring on the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • isotopes of carbon include C-13 and C-14.
  • a number of synthetic routes may be employed to produce the compounds of the invention. In general, they may be synthesized using reactions known in the art. Any art-known method for synthesis may be employed. However, the following synthetic routes are convenient for preparation of the invention compounds. Typical invention compounds are as shown below:
  • Hydroxylamine hydrochloride (12.78 g, 0.184 mole) was dissolved in 40 ml water, treated with sodium hydroxide (7.36 g, 0.184 mole). 60 ml ethanol (anhydrous) was added and while stirring (1-ethoxyethylidene)malonitrile (25 g, 0.184 mole) was added carefully. The reaction mixture was heated to 50° C. for 30 min, then stirred overnight at room temperature. Ethanol was removed under vacuum, the filtered solid product was washed with water, dried under vacuum to obtain 21.93 g (96.8% yield).
  • 3-amino-4-cyano-5-methyl isoxazole (6.0 g, 0.0487 mole) was suspended in acetonitrile/tetrahydrofuran (30 ml/10 ml).
  • Diisopropylethylamine (8.26 ml, 0.0487 mole) was added followed by dropwise addition of 3-chlorobenzoyl chloride. The mixture was stirred at room temperature overnight. The precipitated product was isolated by filtration, washed with chloroform. 1.31 g product were obtained (11% yield).
  • N-(3-chlorobenzoyl)-4-cyano-3-methyl-5-carboxamide (1.0 g, 15 mmole) was suspended in 20 ml 1 M sodium hydroxide and treated with 8 ml 30% hydrogen peroxide. The mixture was refluxed overnight. The cooled reaction mixture was placed on an ice batch and treated with 1 M hydrochloric acid to pH 6. Filtered the product as a white precipitate and dried under vacuum to give 537 mg (53% yield).
  • 3-methyl-6-(3-chlorophenyl) isoxazole[5,4d]pyrimidone (535 mg, 2.04 mmole) was suspended in phosphorus oxychloride (6 ml) and heated to reflux for 4 hours. The excess of phosphorus oxychloride was removed, ice and chloroform (10 ml) were added, basified with saturated sodium bicarbonate, the product into chloroform was extracted and the extracts dried over sodium sulfate (anh). The product was purified by silica gel chromatography eluting with chloroform. 200 mg product was obtained.
  • Benzamidine hydrochloride (4.0 g, 0.25 mol) was dissolved in 64 ml of ethanol. To this 8.0 ml of a 25 wt % solution of sodium methoxide was added. Reaction was then stirred at room temperature for 5 hrs, and filtered. Filtrate was then added to ethyl-2-cyano-4,4-diethoxybutyrate (4.80 g, 0.21 mol). This solution was refluxed for 5 hrs. Half of solvent was removed under reduced pressure, then 80 ml of ice water was added, and the pH was adjusted to 7 with acetic acid. Material was then chilled for 6 hrs and product was isolated by vacuum filtration.
  • 2-phenyl-pyrrolo[2,3d]pyrimidinone (1.0 g 4.73 mmol) was treated with phosphorous oxychloride (7 ml, 27.7 mmol) and refluxed for 5 hrs. Excess phosphorous oxychloride was removed under reduced pressure and then extracted with chloroform, washed with sodium bicarbonate. The organic layer was dried over sodium sulfate (anh), then concentrated to dryness to give the product.
  • 6-hydroxy-5-acetylmethyl-2-(3-chlorophenyl)pyrimidone (5.0 g) was treated with concentrated sulfuric acid (80 ml). The reaction mixture was stirred at room temperature for 4 hours, then neutralized with sodium carbonate and extracted with chloroform, the chloroform extract was washed with water, dried over sodium sulfate (anh) and the solvent was removed to give product (1.10 g).
  • 6-methyl-2-chlorophenyl-furano[3,2-d]pyrimidone (480 mg, 1.84 mmole) was suspended in dichloromethane (4 ml). Thionyl chloride (1.6 ml, 22.5 mmole) and dimethylformamide (0.5 ml) was added and heated to reflux for 3 hours. Excess solvent was removed, the residue was treated with ice, extracted into chloroform, washed with 10% sodium bicarbonate and water, dried over sodium sulfate (anh) and the solvent was removed to give 480 mg product.
  • 6-methyl4-chloro-2-chlorophenyl-furano[3,2d]pyrimidine (480 mg, 1.72 mmole, 1 eq), BINAP (8 mg, 0.013 mmole, 0.0075 eq), Pd 2 (dba) 3 (3.9 mg, 0.0043 mmole, 0.0025 eq), sodium t-butoxide (231 mg, 2.4 mmole, 1.4 eq), 4-aminopyridine (194 mg, 2.06 mmole, 1.2 eq) were combined in 5 ml dioxane and heated to 50° C. for 5 hours. Product was isolated by preparative HPLC on C18 column.
  • Ethyl-2-methyl-5-ethoxy-4-oxazole-4-carboxylate (8.26 g, 41.5 mmol) was treated with 74 ml of a 15% solution of KOH. This was refluxed for 15 minutes then cooled and acidified using a 10% HCl solution. Product was collected by vacuum filtration.
  • 3-chlorobenzamidine (2.29 g, 14.8 mmol) was dissolved in 40 ml of DCM and brought to 0° C. A 15 ml 2.0 M solution of sodium hydroxide was then added. 2-methyl-5-ethoxy-4-oxazole-4-carbonyl chloride (2.8 g, 14.8 mmol), dissolved in 30 ml of DCM was added dropwise to the reaction mixture and stirred at room temperature for 3 hours. Organic solvent was then washed with water followed by sodium bicarbonate, then dried with sodium sulfate and concentrated.
  • Compound of formula (32) was prepared according to the procedure outlined in scheme F, for the preparation of compound of formula (VIII), using 4-aminooyrdine-3-carboxylic acid ethyl ester.
  • Compound of formula (36) was prepared by the method described for the synthesis of compound of formula (20) employing 4-amino-3-trifluoromethyl-picoline in place of 4-amino-3-picoline.
  • Compound of formula (35) was prepared by the method described for the synthesis of compound of formula (21) employing methyl amine in place of ammonia.
  • Compound of formula (37) was prepared by the method described for the synthesis of compound of formula (21) employing pyrrolidine in place of ammonia.
  • Compound of formula (41) was prepared by the method described for the synthesis of compound of formula (21) employing cyclopropylamine in place of ammonia.
  • Compound of formula (42) was prepared by the method described for the synthesis of compound of formula (21) employing cyclopropylmethylamine in place of ammonia.
  • Compound of formula (51) was prepared by the method described for the synthesis of compound of formula (21) employing 2-amino-ethanol in place of ammonia.
  • Compound of formula (52) was prepared by the method described for the synthesis of compound of formula (21) employing 1-amino-propan-2-(S)-ol in place of ammonia.
  • Compound of formula (53) was prepared by the method described for the synthesis of compound of formula (21) employing 3-amino-propane 1,2(S)-diol in place of ammonia.
  • Compound of formula (54) was prepared by the method described for the synthesis of compound of formula (21) employing HO—NH 2 in place of ammonia.
  • Compound of formula (55) was prepared by the method described for the synthesis of compound of formula (21) employing 1-amino-propan-2-(R)-ol in place of ammonia.
  • Compound of formula (56) was prepared by the method described for the synthesis of compound of formula (21) employing N-methylethylenediamine in place of ammonia.
  • Compound of formula (58) was prepared by the method described for the synthesis of compound of formula (21) employing hydrazine in place of ammonia.
  • Compound of formula (67) was prepared by the method described for the synthesis of compound of formula (21) employing benzamidine.
  • Compound of formula (68) was prepared by the method described for the synthesis of compound of formula (21) employing methylamine in place of ammonia and benzamidine in place of 2-F, 3-Cl-benzamidine.
  • Compound of formula (69) was prepared by the method described for the synthesis of compound of formula (21) employing N,N′-dimethyl-1,3-propanediamine in place of ammonia.
  • Compound of formula (70) was prepared by the method described for the synthesis of compound of formula (21) employing 4-(3-aminopropyl)morpholine in place of ammonia.
  • Compound of formula (71) was prepared by the method described for the synthesis of compound of formula (21) employing 1-(3-aminopropyl)imidazole in place of ammonia.
  • Compound of formula (72) was prepared by the method described for the synthesis of compound of formula (21) employing 1-(3-aminopropyl)-2-pyrrolidinone in place of ammonia.
  • Compound of formula (73) was prepared by the method described for the synthesis of compound of formula (21) employing 2-(2-aminoethyl)-1-methylpyrrolidine in place of ammonia.
  • Compound of formula (74) was prepared by the method described for the synthesis of compound of formula (21) employing 1-(3-aminopropyl)-2-pipecoline in place of ammonia.
  • Compound of formula (75) was prepared by the method described for the synthesis of compound of formula (21) employing 1-(2-aminoethyl)pyrrolidine in place of ammonia.
  • Compound of formula (78) was prepared by the method described for the synthesis of compound of formula (21) employing 1-(2-aminoethyl)piperdine in place of ammonia.
  • Compound of formula (79) was prepared by the method described for the synthesis of compound of formula (21) employing N,N-diethylethenediamine in place of ammonia.
  • 1,4-dithian-2,5-diol (4.56 g, 30 mmole) and 2-cyanoacetamide (2.52 g, 30 mmole) were combined in ethanol (50 ml).
  • Triethylamine (6 ml) was added and heated to 70° C. for 1 hour. The volume of solvent was reduced under vacuum, and the product was isolated by filtration. Product was recrystallized from ethanol to give 2.71 g of product (yield 64%).
  • Methylhydrazine (5 g, 108.5 mmole) was added dropwise to a solution of (1-ethoxy-ethylidene)-malonitrile (14.7 g, 108.5 mmole) in 250 ml ethanol. The mixture was then heated to reflux for 2.5 hours. The reaction mixture was allowed to cool, the volume was reduced to about 70 ml and the product was isolated by filtration, washed with cold ethanol and dried to obtain 13.5 g of product (yield: 91%).
  • N-(4-Cyano-2,5-dimethyl-2H-pyrazol-3-yl)-2-fluoro-benzamide (5.0 g, 19.36 mmole) was suspended in 38 ml 1M sodium hydroxide and heated to 90° C. for 3 hours followed by addition of 30% hydrogen peroxide (10 ml) and further heating overnight.
  • the reaction mixture was cooled to room temperature and acidified with dilute hydrochloric acid.
  • the product was isolated by filtration, washed with water, and dried overnight under vacuum to obtain 3.39 g of product. (Yield 67%).
  • 6-(2-Fluoro-phenyl)-1,3-dimethyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one (2.0 g, 7.74 mmole) was treated with 40 ml phosphorous oxychloride and heated to reflux overnight. The excess phosphorous oxychloride was removed under vacuum and ice water was added to the residue. The product was extracted with ethyl acetate, washed with 10% sodium carbonate, water, dried over sodium sulfate (anh) and the solvent was removed to give crude product. Crude product was chromatographed on silica gel column eluting with chloroform to give 1.10 g of pure product (yield: 51%).
  • Butylhydrazine oxalate (14.25 g, 80 mmole) and (1-Ethoxyethylidine)-malonitrile (10.82 g, 80 mmole) were combined in ethanol (200 ml), and the mixture was treated with diisopropylethylamine (10.39 g, 80 mmole). The mixture was refluxed for 2 hours, then stirred at room temperature overnight. Most of the solvent was removed under vacuum and triturated with chloroform, some solid was filtered, and the chloroform filtrate was kept. The chloroform filtrate was washed with water, dried over sodium sulfate (anh) and the solvent was removed to give the product as a solid, 13.13 g (yield: 74%).
  • N-(2-Butyl-4-cyano-5-methyl-2H-pyrazol-3-yl)-2-fluoro-benzamide (4.0 g, 13.3 mmole) was suspended in 26 ml 1M sodium hydroxide, and 30% hydrogen peroxide (10 ml) and ethanol (5 ml) were added. The reaction mixture was heated to reflux for 4 hours, then more 30% hydrogen peroxide (10 ml) was added and heated to reflux overnight. The reaction mixture was cooled and acidified with diluted hydrochloric acid to pH 6.0. The product was collected by filtration and dried under vacuum to obtain 1.29 g of product (yield: 32%).
  • Triethylorthobenzoate 25 g, 0.112 mole
  • malonitrile 9.07 g, 0.137 mole
  • acetic anhydride 50 ml
  • the excess acetic anhydride was removed under vacuum and the product was chromatographed over silica gel eluting with 30% ethylacetate/hexanes to give 21.7 g of product (yield: 97%).
  • reaction mixture was filtered to remove solid material, the filtrate was evaporated to dryness, the residue was dissolved in chloroform (8 ml), washed with 0.5 M sodium hydroxide (1 ml), dried over sodium sulfate (anh.), evaporated to dryness, and then the residue was redissolved in dimethylformamide and purified by reversed phase HPLC. The product was isolated.
  • Compound of formula (81) was prepared using a procedure similar to the one described above, using ethyl 5-chloro-2-fluorobenzoyl acetate.
  • Compound of formula (83) was prepared using a procedure similar to the one described above, using 4-amino-pyrimidine.
  • reaction mixture was cooled to r.t. and filtered through Celite® and the crude material was purified by flash column chromatography (9:1/ethyl acetate:hexane) to afford [2-(5-Chloro-2-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl]-(3-methyl-pyridin-4-yl)-amine, compound of formula (33) (20 mg, 26%) as a white solid.
  • Compound of formula (40) was prepared by the method described for the synthesis of compound of formula (45) employing methylamine in place of cyclopropylamine.
  • Compound of formula (57) was prepared by the method described for the synthesis of compound of formula (45) employing 1-amino-propan-2-(S)-ol in place of cyclopropylamine.
  • Compound of formula (59) was prepared by the method described for the synthesis of compound of formula (45) employing N,N-diethylethanediamine in place of cyclopropylamine
  • reaction mixture was cooled to r.t. and filtered through Celite® and the crude material was purified by flash column chromatography (0-5% MeOH in CHCl 3 ) to afford 4-[2-(5-chloro-2-fluorophenyl)-6,7-dihydrofuro[3,2-d]pyrimidin-4-ylamino]-nicotinic acid ethyl ester (100 mg, 21%) as a white solid.
  • Compounds of formula (1) may be converted into each other following art-known functional group transformation reactions, comprising those described hereinafter.
  • a number of the intermediates used to prepare the compounds of formula (1) are known compounds or are analogs of known compounds, which can be prepared following modifications of art-known methodologies readily accessible to the skilled person.
  • the compounds of formula (1) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form.
  • Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (1) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide;
  • appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarboperoxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert-butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
  • the compounds of formula (1) may be obtained as racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
  • the racemic compounds of formula (1) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (1) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • said compound may be synthesized by stereospecific methods of preparation. These methods may advantageously employ enantiomerically pure starting materials.
  • compositions for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • a therapeutically effective amount of the particular compound, optionally in addition salt form or metal complex, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a therapeutically effective amount in this context is an amount sufficient to prophylactically act against, to stabilize or to reduce viral infection, and in particular HCV viral infection, or to prevent disease progression towards chronic hepatitis, liver fibrosis, cirrhosis, end-stage liver disease, HCC (hepatocellular carcinoma) and the like, in infected subjects or subjects being at risk of being infected.
  • compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • the compounds of the invention are small molecules, they are conveniently administered by oral administration by compounding them with suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like.
  • suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like.
  • suitable formulations for oral administration may also include minor components such as buffers, flavoring agents and the like.
  • the amount of active ingredient in the formulations will be in the range of 5%-95% of the total formulation, but wide variation is permitted depending on the carrier.
  • Suitable carriers include sucrose, pectin, magnesium stearate, lactose, peanut oil, olive oil, water, and the like.
  • the compounds useful in the invention may also be administered through suppositories or other transmucosal vehicles.
  • formulations will include excipients that facilitate the passage of the compound through the mucosa such as pharmaceutically acceptable detergents.
  • the compounds may also be administered topically, for topical conditions such as psoriasis, or in formulation intended to penetrate the skin.
  • topical conditions such as psoriasis
  • formulation intended to penetrate the skin include lotions, creams, ointments and the like which can be formulated by known methods.
  • the compounds may also be administered by injection, including intravenous, intramuscular, subcutaneous or intraperitoneal injection.
  • Typical formulations for such use are liquid formulations in isotonic vehicles such as Hank's solution or Ringer's solution.
  • the compounds of the present invention may also be administered via oral inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the administration of the present compounds.
  • the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (1) and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (1) and a pharmaceutically acceptable carrier.
  • the compounds of the present invention are administered via inhalation of a solution in nebulized or aerosolized doses.
  • Alternative formulations include nasal sprays, liposomal formulations, slow-release formulations, and the like, as are known in the art.
  • Any suitable formulation may be used.
  • a compendium of art-known formulations is found in Remington's Pharmaceutical Sciences , latest edition, Mack Publishing Company, Easton, Pa. Reference to this manual is routine in the art.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the dosages of the compounds of the invention will depend on a number of factors which will vary from patient to patient. However, it is believed that generally, the daily oral dosage will utilize 0.001-100 mg/kg total body weight, preferably from 0.01-50 mg/kg and more preferably about 0.01 mg/kg-10 mg/kg. The dose regimen will vary, however, depending on the conditions being treated and the judgment of the practitioner.
  • an antiviral effective daily amount would be from 0.01 mg/kg to 500 mg/kg body weight, more preferably from 0.1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.
  • the compounds of the present invention are useful in the treatment of individuals infected by HCV and for the prophylaxis of these individuals.
  • the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with flaviviruses.
  • Conditions which may be prevented or treated with the compounds of the present invention especially conditions associated with HCV and other pathogenic flaviviruses, such as Yellow fever, Dengue fever (types 1-4), St. Louis encephalitis, Japanese encephalitis, Murray valley encephalitis, West Nile virus and Kunjin virus.
  • the conditions associated with HCV include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and HCC; and for the other pathogenic flaviruses the conditions include yellow fever, dengue fever, haemorraghic fever and encephalitis.
  • the compounds of the present invention or any subgroup thereof may therefore be used as medicines against the above-mentioned conditions.
  • Said use as a medicine or method of treatment comprises the systemic administration to HCV-infected subjects of an amount effective to combat the conditions associated with HCV and other pathogenic flaviviruses. Consequently, the compounds of the present invention can be used in the manufacture of a medicament useful for treating conditions associated with HCV and other pathogenic flaviviruses.
  • the invention relates to the use of a compound of formula (1) or any subgroup thereof as defined herein in the manufacture of a medicament for treating or combating infection or disease associated with HCV infection in a mammal.
  • the invention also relates to a method of treating a flaviviral infection, or a disease associated with flavivirus infection comprising administering to a mammal in need thereof an effective amount of a compound of formula (1) or a subgroup thereof as defined herein.
  • the present invention relates to the use of formula (1) or any subgroup thereof as defined herein for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with flaviviruses, in particular HCV.
  • the present invention relates to the use of formula (1) or any subgroup thereof as defined herein for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with flaviviruses, wherein said HCV is inhibited in its replication.
  • the compounds of formula (1) can be administered as individual active ingredients, or as mixtures of several embodiments of this formula.
  • the compounds of the invention may be used as single therapeutic agents or in combination with other therapeutic agents.
  • the combination of previously known anti-HCV compound such as, for instance, interferon- ⁇ (IFN- ⁇ ), pegylated interferon- ⁇ and/or ribavirin, and a compound of the present invention can be used as a medicine in a combination therapy.
  • the term “combination therapy” relates to a product containing mandatory (a) a compound of the present invention, and (b) optionally another anti-HCV compound, as a combined preparation for simultaneous, separate or sequential use in treatment of HCV infections, in particular, in the treatment of infections with HCV type 1.
  • the compounds of this invention may be co-administered in combination with for instance, interferon- ⁇ (IFN- ⁇ ), pegylated interferon- ⁇ and/or ribavirin, as well as therapeutics based on antibodies targeted against HCV epitopes, small interfering RNA (Si RNA), ribozymes, DNAzymes, antisense RNA, small molecule antagonists of for instance NS3 protease, NS3 helicase and NS5B polymerase.
  • IFN- ⁇ interferon- ⁇
  • Si RNA small interfering RNA
  • ribozymes DNAzymes
  • DNAzymes DNAzymes
  • antisense RNA small molecule antagonists of for instance NS3 protease
  • NS3 helicase and NS5B polymerase small RNA
  • the present invention relates to the use of a compound of formula (1) or any subgroup thereof as defined above for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV viruses, wherein said medicament is used in a combination therapy, said combination therapy preferably comprising a compound of formula (1) and (pegylated) IFN- ⁇ and/or ribavirin, and possibly an anti-HIV compound.
  • the compounds of the present invention were examined for activity in the inhibition of HCV RNA replication in a cellular assay.
  • the assay demonstrated that the present compounds exhibited activity against HCV replicons functional in a cell culture.
  • the cellular assay was based on a bicistronic expression construct, as described by Lohmann et al. (1999) Science vol. 285 pp. 110-113 with modifications described by Krieger et al. (2001) Journal of Virology 75: 4614-4624, in a multi-target screening strategy. In essence, the method was as follows.
  • the assay utilized the stably transfected cell line Huh-7 luc/neo (hereafter referred to as Huh-Luc).
  • Huh-Luc This cell line harbored an RNA encoding a bicistronic expression construct comprising the wild type NS3-NS5B regions of HCV type 1b translated from an Internal Ribosome Entry Site (IRES) from encephalomyocarditis virus (EMCV), preceded by a reporter portion (FfL-luciferase), and a selectable marker portion (neo R , neomycine phosphotransferase).
  • IRS Internal Ribosome Entry Site
  • EMCV encephalomyocarditis virus
  • FfL-luciferase reporter portion
  • neo R selectable marker portion
  • the replicon cells were plated in 384 well plates in the presence of the test and control compounds which were added in various concentrations. Following an incubation of three days, HCV replication was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLuxTM ultraHTS microplate imager). Replicon cells in the control cultures had high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound on luciferase activity was monitored on the Huh-Luc cells, enabling a dose-response curve for each test compound. EC50 values were then calculated, which value represented the amount of the compound required to decrease by 50% the level of detected luciferase activity, or more specifically, the ability of the genetically linked HCV replicon RNA to replicate.
  • column 1 provides an identification number
  • column 2 displays the results on the above described Huh7-Luc assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
US11/684,288 2004-09-30 2007-03-09 HCV inhibiting bi-cyclic pyrimidines Expired - Fee Related US7977342B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04104815.8 2004-09-30
EP04104815 2004-09-30
EP05102810.8 2005-04-08
EP05102810 2005-04-08
PCT/EP2005/054912 WO2006035061A1 (fr) 2004-09-30 2005-09-29 Pyrimidines bicycliques inhibant le vhc
EPPCT/EP05/54912 2005-09-29

Publications (2)

Publication Number Publication Date
US20070155716A1 US20070155716A1 (en) 2007-07-05
US7977342B2 true US7977342B2 (en) 2011-07-12

Family

ID=35448001

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/684,288 Expired - Fee Related US7977342B2 (en) 2004-09-30 2007-03-09 HCV inhibiting bi-cyclic pyrimidines

Country Status (15)

Country Link
US (1) US7977342B2 (fr)
EP (1) EP1799218A1 (fr)
JP (1) JP5046942B2 (fr)
KR (1) KR20070058602A (fr)
CN (1) CN100594903C (fr)
AP (1) AP2007003923A0 (fr)
AR (1) AR052771A1 (fr)
AU (1) AU2005288858B2 (fr)
BR (1) BRPI0516751A (fr)
CA (1) CA2577745C (fr)
IL (1) IL181226A (fr)
NO (1) NO20072235L (fr)
RU (1) RU2380101C2 (fr)
TW (1) TW200626157A (fr)
WO (1) WO2006035061A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174995B2 (en) 2012-05-04 2015-11-03 Merck Patent Gmbh Pyrrolotriazinone derivatives
WO2016067099A1 (fr) 2014-10-29 2016-05-06 King Abdullah University Of Science And Technology Composé de 3-alkyle pyridinium à partir d'éponge marine rouge avec une activité antivirale puissante
US10030004B2 (en) 2014-01-01 2018-07-24 Medivation Technologies Llc Compounds and methods of use
US11104674B2 (en) 2016-06-29 2021-08-31 Hoffmann-La Roche Inc. Tetrahydropyridopyrimidines for the treatment of HBV infection

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040966A1 (fr) * 2004-10-08 2006-04-20 Astellas Pharma Inc. Dérivé polycyclique aromatique de pyrimidine
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
WO2006073610A2 (fr) * 2004-11-23 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP1869037B1 (fr) * 2005-03-25 2011-07-27 Tibotec Pharmaceuticals Inhibiteurs heterobicycliques du vhc
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
AR056347A1 (es) * 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2007011759A2 (fr) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
CA2633757A1 (fr) 2005-12-21 2007-07-05 Abbott Laboratories Composes antiviraux
EP1971611B1 (fr) * 2005-12-21 2012-10-10 Abbott Laboratories Composes anti-viraux
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
DE102006029074A1 (de) * 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
WO2008021456A2 (fr) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose, et leurs utilisations
WO2008133753A2 (fr) 2006-12-20 2008-11-06 Abbott Laboratories Composés antiviraux
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2134716A1 (fr) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
CN101981037B (zh) * 2008-01-30 2013-09-04 吉宁特有限公司 吡唑并嘧啶pi3k抑制剂化合物及使用方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100015141A1 (en) * 2008-07-21 2010-01-21 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
ES2432821T3 (es) 2008-07-31 2013-12-05 Genentech, Inc. Compuestos de pirimidina, composiciones y métodos de utilización
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2744154A1 (fr) 2008-11-20 2010-05-27 Genentech, Inc. Composes inhibiteurs de pi3k de type pyrazolopyridine et leurs procedes d'utilisation
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2010071885A1 (fr) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines en tant qu'inhibiteurs d'alk et de jak2
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (fr) 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2499143B1 (fr) 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag Composés des purines n7-substituées et des pyrazolopyrimidines, compositions et les procédés pour leur utilisation
US8288381B2 (en) 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
EP3290428B1 (fr) 2010-03-31 2021-10-13 Gilead Pharmasset LLC Comprimé contenant cristallin (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
DK2552930T3 (en) 2010-03-31 2015-12-07 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-DIHYDROPYRIMIDIN- 1- (2 H) -yl) - 4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20150047609A (ko) 2012-08-30 2015-05-04 니뽄 신야쿠 가부시키가이샤 피리딘 유도체 및 의약
KR20150056844A (ko) * 2012-09-17 2015-05-27 아비에 도이치란트 게엠베하 운트 콤파니 카게 포스포디에스테라제 타입 10a의 신규 억제제 화합물
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
JP6307524B2 (ja) * 2013-02-04 2018-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｐｄｅ４阻害薬としての、４−アミノ置換縮合ピリミジン化合物
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
EP3240537B1 (fr) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Nouvelles tétrahydropyridopyrimidines et tétrahydropyridopyridines pour le traitement et la prévention d'une infection par le virus de l'hépatite b
EP3341372A1 (fr) * 2015-08-25 2018-07-04 Bristol-Myers Squibb Company Antagonistes du récepteur tgf bêta
US9963462B2 (en) 2015-09-30 2018-05-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Sepiapterin reductase inhibitors
MX2018011786A (es) * 2016-04-01 2019-05-20 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
CN111548349A (zh) * 2020-05-13 2020-08-18 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2000012497A2 (fr) 1998-08-28 2000-03-09 Scios Inc. Derives de quinazoline utilisables comme medicaments
WO2001047921A1 (fr) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
WO2002022601A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase
WO2002076976A2 (fr) 2001-03-23 2002-10-03 Bayer Corporation Inhibiteurs de rho-kinase
WO2003078427A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines inhibitrices des proteines kinases
WO2003078423A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions s'utilisant comme inhibiteurs de proteine kinases
WO2003078426A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
WO2003077921A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles utilises comme inhibiteurs de proteine kinases
WO2003097615A1 (fr) 2002-05-17 2003-11-27 Scios, Inc. Traitement de troubles de fibro-proliferation au moyen d'inhibiteur de tgf-$g(b)
WO2004048930A2 (fr) 2002-11-22 2004-06-10 Scios, Inc. METHODE PERMETTANT DE CONTRER UN CHANGEMENT PATHOLOGIQUE DANS LA VOIE ss-ADRENERGIQUE
WO2004047818A2 (fr) 2002-11-22 2004-06-10 Scios, Inc. UTILISATION D'INHIBITEURS DE TGF-$G(B) POUR CONTREBALANCER LES MODIFICATIONS PATHOLOGIQUES DU TAUX OU DE LA FONCTION DE RECEPTEURS STEROIDIENS/THYROIDIENS
WO2004065392A1 (fr) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
WO2004074270A2 (fr) 2003-02-21 2004-09-02 Pfizer Inc. Inhibiteurs de l'arn polymerase arn-dependante du virus de l'hepatite c, et compositions et traitements faisant appel a cet inhibiteur
WO2004087056A2 (fr) 2003-03-28 2004-10-14 Scios Inc. Inhibiteurs bi-cycliques a base de pyrimidine de tgf$g(b)
WO2005032481A2 (fr) 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
WO2006100310A1 (fr) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Inhibiteurs heterobicycliques du vhc
WO2006105063A1 (fr) 2005-03-25 2006-10-05 Scios Inc. Inhibiteurs bicycliques fusionnes de tgf$g(b)
US20090131460A1 (en) 2005-05-12 2009-05-21 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
US20090156595A1 (en) 2005-05-12 2009-06-18 Tibotec Pharmaceuticals Ltd. Pteridines useful as HCV inhibitors and methods for the preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123328C1 (ru) * 1996-04-19 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Липосомальное противовирусное лекарственное средство для перорального применения

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2000012497A2 (fr) 1998-08-28 2000-03-09 Scios Inc. Derives de quinazoline utilisables comme medicaments
US6476031B1 (en) 1998-08-28 2002-11-05 Scios, Inc. Quinazoline derivatives as medicaments
WO2001047921A1 (fr) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Composes de pyrimidine et de triazine presentant une activite inhibant la kinase
WO2002022601A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase
WO2002076976A2 (fr) 2001-03-23 2002-10-03 Bayer Corporation Inhibiteurs de rho-kinase
WO2003078427A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines inhibitrices des proteines kinases
WO2003078423A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions s'utilisant comme inhibiteurs de proteine kinases
WO2003078426A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
WO2003077921A1 (fr) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles utilises comme inhibiteurs de proteine kinases
WO2003097615A1 (fr) 2002-05-17 2003-11-27 Scios, Inc. Traitement de troubles de fibro-proliferation au moyen d'inhibiteur de tgf-$g(b)
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
WO2004048930A2 (fr) 2002-11-22 2004-06-10 Scios, Inc. METHODE PERMETTANT DE CONTRER UN CHANGEMENT PATHOLOGIQUE DANS LA VOIE ss-ADRENERGIQUE
WO2004047818A2 (fr) 2002-11-22 2004-06-10 Scios, Inc. UTILISATION D'INHIBITEURS DE TGF-$G(B) POUR CONTREBALANCER LES MODIFICATIONS PATHOLOGIQUES DU TAUX OU DE LA FONCTION DE RECEPTEURS STEROIDIENS/THYROIDIENS
WO2004065392A1 (fr) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
WO2004074270A2 (fr) 2003-02-21 2004-09-02 Pfizer Inc. Inhibiteurs de l'arn polymerase arn-dependante du virus de l'hepatite c, et compositions et traitements faisant appel a cet inhibiteur
WO2004087056A2 (fr) 2003-03-28 2004-10-14 Scios Inc. Inhibiteurs bi-cycliques a base de pyrimidine de tgf$g(b)
WO2005032481A2 (fr) 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
WO2006100310A1 (fr) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Inhibiteurs heterobicycliques du vhc
WO2006105063A1 (fr) 2005-03-25 2006-10-05 Scios Inc. Inhibiteurs bicycliques fusionnes de tgf$g(b)
US20080182863A1 (en) 2005-03-25 2008-07-31 Kenneth Alan Simmen Fused Bicyclic Inhibitors of Hcv
US20090131460A1 (en) 2005-05-12 2009-05-21 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
US20090156595A1 (en) 2005-05-12 2009-06-18 Tibotec Pharmaceuticals Ltd. Pteridines useful as HCV inhibitors and methods for the preparation thereof

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
Bernard Testa, "Prodrug Research: Futile or Fertile?" Biochemical Pharmacology 68: 2097-2106, 2004.
Choo, Qui-Lim et al., "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome", Science, Apr. 21, 1989, pp. 359-362, vol. 244.
Cooper, Kelvin et al., "Bicyclo[3.3.0]octenones in Synthesis. An Approach to the Synthesis of the Antitumor Sesquiterpene Quadrone", J. Chem. Soc. Perkin Trans., 1984, pp. 799-809, vol. 1.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. *
Dowd, Paul et al., "Free Radical Ring-Expansion Leading to Novel Six- and Seven-Membered Heterocycles", Tetrahedron, 1991, pp. 4847-4860, vol. 47, No. 27.
Ettmayer et al., "Lessons Learned from Marketed and Investigational Prodrugs," Journal of Medicinal Chemistry, 47(10): 2393-2404, 2004.
Goodman & Gilman's the Pharmacological Basis of Therapeutics.
Greco, Michael N. et al., "Highly Stereoselective Synthesis of Substituted Hydrindanes Related to the Antiepileptic Drug Topiramate", Tetrahedron Letters, 1992, pp. 5009-5012, vol. 33, No. 35.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/909,118 dated Jul. 13, 2009, 11 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/914,044 dated Apr. 29, 2010, 7 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/909,118 dated Dec. 30, 2008, 15 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/914,044 dated Sep. 3, 2009, 11 pages.
Kim, W. Ray, "The Burden of Hepatitis C in the United States", Hepatology, 2002, pp. 530-534, vol. 36, No. 5, Suppl. 1.
Kimura, et. al., Journal of Infectious Diseases, (2006); 193, 1371-4. *
Kolykhalov, Alexander A. et al., "Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3' Nontranslated Region Are Essential for Virus Replication In Vivo", Journal of Virology, Feb. 2000, pp. 2046-2051, vol. 74, No. 4.
Krieger, Nicole et al., "Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations", Journal of Virology, May 2001, pp. 4614-4624, vol. 75, No. 10.
Lauer, Georg M. et al., "Hepatitis C Virus Infection", New Engl. J. Med., Jul. 5, 2001, pp. 41-52, vol. 345, No. 1.
Lohmann, V. et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line", Science, Jul. 2, 1999, pp. 110-113, vol. 285.
Manfred E. Wolff, "Some Considerations for Prodrug Design," Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., vol. 1, 975-977, 1994.
Moyer, Mikel P. et al., Intramolecular N-H, O-H and S-H Insertion Reactions. Synthesis of Heterocycles from alpha-Diazo beta-Keto Esters, J. Org. Chem., 198, pp. 5223-5230, vol. 50, year issued: 1985.
Moyer, Mikel P. et al., Intramolecular N-H, O-H and S-H Insertion Reactions. Synthesis of Heterocycles from α-Diazo β-Keto Esters, J. Org. Chem., 198, pp. 5223-5230, vol. 50, year issued: 1985.
Murata et al., "Suppression of Hepatitis C Virus Replicon by TGF-beta," Virology, 331: 407-417, 2005.
Murata et al., "Suppression of Hepatitis C Virus Replicon by TGF-β," Virology, 331: 407-417, 2005.
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-Jun. 10-12, 2002, Hepatology, Nov. 2002, pp. S3-S-20.
Valentino J. Stella, "Prodrugs as Therapeutics," Expert Opinion on Therapeutic Patents, 14(3): 277-280, 2004.
Wolff, Manfred E. et al., Thia Steroids. III. Derivatives of 2-Thia-A-nor-5alpha-androstan-17beta-ol As Probes of Steroid-Receptor Interactions, Journal of Medicinal Chemistry, 1970, pp. 531-534, vol. 13, No. 3.
Wolff, Manfred E. et al., Thia Steroids. III. Derivatives of 2-Thia-A-nor-5α-androstan-17β-ol As Probes of Steroid-Receptor Interactions, Journal of Medicinal Chemistry, 1970, pp. 531-534, vol. 13, No. 3.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174995B2 (en) 2012-05-04 2015-11-03 Merck Patent Gmbh Pyrrolotriazinone derivatives
US10030004B2 (en) 2014-01-01 2018-07-24 Medivation Technologies Llc Compounds and methods of use
US10501436B2 (en) 2014-01-01 2019-12-10 Medivation Technologies Llc Compounds and methods of use
US11053216B2 (en) 2014-01-01 2021-07-06 Medivation Technologies Llc Compounds and methods of use
US11702401B2 (en) 2014-01-01 2023-07-18 Medivation Technologies Llc Compounds and methods of use
WO2016067099A1 (fr) 2014-10-29 2016-05-06 King Abdullah University Of Science And Technology Composé de 3-alkyle pyridinium à partir d'éponge marine rouge avec une activité antivirale puissante
US10376498B2 (en) 2014-10-29 2019-08-13 King Abdullah University Of Science And Technology 3-alkyl pyridinium compound from red sea sponge with potent antiviral activity
US11104674B2 (en) 2016-06-29 2021-08-31 Hoffmann-La Roche Inc. Tetrahydropyridopyrimidines for the treatment of HBV infection

Also Published As

Publication number Publication date
EP1799218A1 (fr) 2007-06-27
WO2006035061A1 (fr) 2006-04-06
RU2007116176A (ru) 2008-11-10
AR052771A1 (es) 2007-04-04
BRPI0516751A (pt) 2008-09-16
CA2577745A1 (fr) 2006-04-06
US20070155716A1 (en) 2007-07-05
AU2005288858A1 (en) 2006-04-06
CA2577745C (fr) 2012-11-27
RU2380101C2 (ru) 2010-01-27
IL181226A (en) 2015-03-31
JP2008514678A (ja) 2008-05-08
KR20070058602A (ko) 2007-06-08
TW200626157A (en) 2006-08-01
JP5046942B2 (ja) 2012-10-10
CN101031304A (zh) 2007-09-05
IL181226A0 (en) 2007-07-04
CN100594903C (zh) 2010-03-24
AU2005288858B2 (en) 2011-04-21
AP2007003923A0 (en) 2007-02-28
NO20072235L (no) 2007-06-28

Similar Documents

Publication Publication Date Title
US7977342B2 (en) HCV inhibiting bi-cyclic pyrimidines
US11225482B2 (en) Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US7223766B2 (en) Bi-cyclic pyrimidine inhibitors of TGFβ
US8022077B2 (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US9708328B2 (en) Pteridines useful as HCV inhibitors and methods for the preparation thereof
EP1869037B1 (fr) Inhibiteurs heterobicycliques du vhc
US7989471B2 (en) Macrocyclic inhibitors of hepatitis C virus
US20070066632A1 (en) Fused bicyclic inhibitors of TGFbeta
US20090247523A1 (en) Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
WO2007026024A2 (fr) Benzodiazepines en tant qu'inhibiteurs du vhc
US9493461B2 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
MX2007002450A (es) Pirimidinas biciclicas inhibidoras del virus de la hepatitis c.
CN101171014B (zh) 可用作hcv抑制剂的蝶啶类物质及其制备方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: TIBOTEC BVBA, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMMEN, KENNETH ALAN;LIN, TSE-I;LENZ, OLIVER;AND OTHERS;REEL/FRAME:019015/0971

Effective date: 20051016

AS Assignment

Owner name: TIBOTEC PHARMACEUTICALS LTD., IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TIBOTEC BVBA;REEL/FRAME:026028/0397

Effective date: 20051020

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190712

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载